BCR-ABL type of mutation and hematology response to imatinib mesylate in chronic phase CML patient: a retrospective study in a tertiary referral hospital in Indonesia
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 2, Pages 1820-1830
AbstractBackground: The BCR-ABL mutation types were reported influencing the treatment of
Chronic Myelogenous Leukemia (CML) due to different responses to the use of tyrosine
kinase inhibitor. However, the clinical score system, that is, EUTOS score is also
considered as one essential factor in determining the treatment outcome. This study aims at
observing the hematology response among chronic phase CML patients atSardjito Hospital
Yogyakarta, Indonesia based on BCR-ABLmutation types, namely b3a2 and non-b3a2,
with evaluation of EUTOS scores.
Methods: A retrospective cohort of 72 subjects from January 2013 to November 2018 was
analyzed according to mutation types and EUTOS scores to observe the hematological
response within 6 months after initiation of Imatinib therapy.
Results: Forty-eight subjects (66.7%) had b3a2 mutations, while others had non-b3a2
mutations. The median of spleen size was significantly higher in non-b3a2 mutations (p =
0.024). Only 49 subjects (68%) achieved the complete hematological response (CHR) within
6 months. The non-b3a2 mutation subjects were likely to have worse clinical and laboratory
profiles than the b3a2 mutation subjects did (p > 0.05). The b3a2 mutation subjects tended
toachieve earlier CHR than non-b3a2 mutation subjects (HR 1.031; p = 0.919). The latter
subjects with high EUTOS scores had longer time to achieve the CHR (p = 0.781).
- Article View: 49
- PDF Download: 92